Clinical input is essential. Carrying the whole production is not.
Good medical content needs a doctor — but for the clinical substance and the approval, not for the writing, formatting, translating and publishing. The efficient model is a clear split: the doctor supplies and signs off the facts; everything else is produced around that input. Full production should not depend on the doctor finding several free hours after a day of consultations.
Content stalls not because the doctor cannot write, but because writing a proper page competes with patients — and patients win. So the page stays thin, or a junior draft goes up unreviewed. Neither is the right trade, and in a field like fertility — where wording carries emotional weight and the evidence is nuanced — an unreviewed page is a real risk.
The division of labour
The doctor provides: treatment details, clinic-specific differences, correct terminology, the limitations that must be stated, and final approval of any claim.
The production side handles: topic and question research, structure, patient-friendly writing, formatting, metadata, illustrations, translation and localisation, and publish-ready assets.
The doctor’s time goes to judgement, not typing.
What a good review actually looks like
Concretely, in a fertility context: the production side drafts the page on, say, what a first IVF cycle involves — structured, in plain language, in the required languages. The clinician’s review is fast and high-value: confirm the pathway matches how the clinic actually works, correct any terminology, flag where success rates must be framed carefully and never overstated, and mark anything that needs an individual-consultation caveat. That is a focused pass on the substance — not a rewrite. 〈CLAIM: illustrative division of labour, clinician holds final judgement〉
Where AI fits
This split is exactly where AI fits: it accelerates the production side — drafting, structuring, simplifying, multilingual drafting — while the doctor stays in control of substance and sign-off. AI without the review step is the failure mode; review without production help is the time sink. The point is to make oversight fast, not to remove it.
What not to do
- Do not publish AI or junior drafts without clinical sign-off — especially where success rates or outcomes are described.
- Do not turn the doctor into the writer; that recreates the bottleneck the split exists to remove.
- Do not let the review balloon into a rewrite — the draft should arrive good enough that review is a focused pass.
Common questions
- If I only review, is it really my content?
- Yes — you define the facts and approve every claim; authorship of substance is yours.
- How long should review take?
- Usually a focused briefing and review, not the hours required to research, write and format the page yourself.
- What if the draft gets the medicine wrong?
- You catch it at review — that is the point of the step. Nothing publishes without your sign-off.
Turn one treatment into a complete patient-education content block
You supply the clinical substance; we produce the rest, ready to publish.
